Gryt’s differentiator is trusted, authentic patient insights, not just data capture. A patient-centered engagement and insights platform purpose-built for life sciences, with scalable, trusted access to longitudinal patient and caregiver perspectives across disease areas.
Gryt functions as a patient engagement enrichment layer and patient validation engine, embedded directly into pharma and life sciences workflows.
Adds lived-experience intelligence to existing research and strategy infrastructure.
Validates insights used in brand strategy, medical education, advisory boards, and launch excellence.
AI-enabled synthesis accelerates time-to-insight while staying grounded in real patient dialogue.
Research and education increasingly judged on credibility, authenticity, and real-world relevance. Gryt delivers all three.
A full-service advisory board and patient experience research partner, delivering results that optimize trial recruitment and refine advocacy and commercial strategy.
Co-developed protocol and led study activities for 200 patients with solid tumor and MM to understand awareness of cancer-related bone health and improve education for patients at risk of SREs.
Roundtables with systemic mastocytosis patients to surface lived-experience insights for global patient affairs strategy.
Focus groups on burden of illness and potential patient-reported outcomes to inform trial design.
12 statements of work from 2017 to 2023 driving advocacy and commercialization strategy, resulting in 7 posters and peer-reviewed publications.
Research with patients considering and undergoing CAR T treatment, informing therapeutic strategy and innovation.
Ad boards with mCRC patients to refine promotional materials and define the product brand.
Amgen’s XGEVA team had questions about bone health in cancer patients that required answers from patients themselves, not from doctors or the healthcare system.
Gryt worked with Amgen to design the BonE heAlth eduCatiOn Needs assessment (BEACON), a survey of multiple myeloma and bone metastatic solid tumor patients at risk for skeletal-related events, and led the study from protocol through publication.
“I think your company’s platform is unique and will undoubtedly improve both the OS and QoL for patients. Results from the BEACON project will be used to form the basis for meaningful scientific exchange towards awareness of an ongoing medical need.”
Benoit Cadieux, PhD, former Head Medical Affairs, Amgen
